Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



@@#116300@@

Journal of the American Academy of Dermatology
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le vendredi 31 janvier 2020
Doi : 10.1016/j.jaad.2019.10.067
accepted : 30 October 2019
Detection of subclinical disease with baseline and surveillance imaging in high-risk cutaneous squamous cell carcinomas
 

Jacqueline M. Maher, BA a, Chrysalyne D. Schmults, MD, MSCE b, Fadi Murad, MPH b, Pritesh S. Karia, MPH c, Carol B. Benson, MD d, Emily Stamell Ruiz, MD, MPH b,
a New York Medical College, Valhalla, New York 
b Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts 
c Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 
d Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts 

Correspondence to: Emily Stamell Ruiz, MD, MPH, Department of Dermatology, Brigham and Women's Hospital, 1153 Centre Street, Ste 4J, Jamaica Plain, MA 02130.Department of DermatologyBrigham and Women's Hospital1153 Centre Street, Ste 4J, Jamaica PlainMA02130
Abstract
Background

There are limited studies on imaging for management of high-risk cutaneous squamous cell carcinoma (HRCSSC).

Objective

To evaluate the impact of baseline (ie, at diagnosis) and surveillance (ie, subsequent time points after diagnosis) imaging on management of HRCSCCs.

Methods

All primary CSSCs treated at Brigham and Women's Hospital Mohs Surgery Clinic and Dana-Farber Cancer Institute High-Risk Skin Cancer Clinic from January 1, 2017 through June 1, 2019, were reviewed to identify tumors that underwent baseline or surveillance imaging. Tumors that underwent imaging were reviewed to determine the impact of imaging on management and ability of imaging to identify subclinical disease.

Results

Eighty-three patients underwent imaging for 87 primary HRCSCCs, of which 48 (58%) underwent surveillance imaging. A total of 146 (59%) abnormal results were obtained from 248 imaging studies. Management was altered by 42 (24%) studies. Imaging detected subclinical disease in 21% of cases studied. A majority (56%) of detections were not seen initially but rather during surveillance imaging in the 2 years after treatment.

Limitations

Single institution retrospective design.

Conclusions

Imaging identifies subclinical disease in HRCSCC. Prospective studies are needed to determine best practices for screening and surveillance in HRCSCC.

The full text of this article is available in PDF format.

Key words : cutaneous squamous cell carcinoma, imaging, metastasis, poor outcomes, skin cancer

Abbreviations used : AJCC 8, BWH, CSCC, CT, DM, MRI, NM, PET



 Funding sources: Supported by a Cancer Epidemiology, Prevention, and Control Training Grant (NCI T32 CA009314 to Mr Karia).
 Conflicts of interest: None disclosed.
 IRB approval status: Approved by Partners Research Committee.
 Reprints not available from the authors.



© 2019  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline